Who We Are: PMK Group and Our Mission in Biotech

The hidden truth of biotech failures.

Biotech is often described as high risk. The narrative focuses on the science of whether a molecule will work, whether a new therapy will deliver results. But the numbers tell a different story. Almost 60 percent of clinical trial failures are not about the molecule itself. They are about execution. Protocols that are poorly designed. Clinical sites that are not prepared. Regulatory frameworks that are not aligned. These are technical failures, not scientific ones. And they cost billions.

At PMK Group, this is the problem we set out to solve.

From science to execution

My own journey began in pharmacology. I trained as a clinical pharmacologist in Hungary, moved into clinical research, and later into investment. Along the way, I saw the same pattern repeat across continents: science that had promise, but execution that failed.

I saw brilliant ideas collapse because of avoidable mistakes in trial design. I saw investors lose capital because operations lagged behind ambition. I saw timelines stretched by years simply because regulatory strategy was an afterthought.

Biotech is not broken because of a lack of vision. It is broken because execution is not treated with the same seriousness as discovery.

Why PMK Group exists

PMK Group was created with a simple mission: to bring discipline, expertise, and operational depth into the biotech investment process. We are not traditional investors. We do not stop at writing a cheque. We step into the process.

That means three things:

1. Expert involvement from the start: We work with founders to design protocols, align regulatory frameworks, and map development strategies that avoid avoidable failures.
2. Embedded operational support: We bring clinical research teams, site partnerships, and regulatory know-how directly into portfolio companies.
3. Shared risk and alignment: We invest not only capital, but also our reputation and our systems. Our success is tied to execution, not just valuation.

Reducing risk, accelerating outcomes.

The difference is visible. By engaging deeply, we reduce technical failure rates, cut timelines, and create more capital-efficient paths to milestones. For investors, this means de-risked exposure. For founders, it means faster progress with fewer blind spots. For society, it means therapies that reach patients sooner.

Learning from failure

This model is not theoretical. It was born out of my own failures.

In 2007, I founded CRU Hungary, the first private clinical research unit embedded within government hospitals. We were faster, more efficient, and more patient-centered than traditional university centers. Over the next decade, we expanded into multiple countries.

But in 2020, COVID changed everything. Governments shut down facilities overnight. Clinics in Frankfurt and Hanoi were lost. Millions in investment disappeared in days.

That was the moment I realised fixed infrastructure was no longer safe. We rebuilt the model. Instead of owning facilities, we embedded ourselves into partner hospitals. More agile, more capital efficient, and less vulnerable to political disruption.

That shift became the foundation for PMK Group’s current approach.

Why this matters for investors

Investors do not fear science risk. They expect it. What they fear is wasting years and millions on trials that fail for reasons that should have been prevented.

By combining capital with expertise, PMK Group provides investors with a rare asset in biotech: operational leverage.

For private equity firms, this means portfolio companies with stronger infrastructure and faster exit paths.

For venture capital, it means early-stage biotech and medtech startups with executional depth.

For family offices, it means meaningful investments with reduced downside risk.

Our mission

At PMK Group, we believe biotech investment should not be speculation. It should be a partnership built on shared expertise and aligned outcomes.

We exist to reduce technical failures, accelerate development, and ensure that promising therapies do not get lost in the gap between science and execution.

Because in biotech, success is not just about the idea. It is about building the systems that bring the idea to life.

Looking ahead

The next decade in biotech will not be defined by how many molecules are discovered. It will be defined by how effectively they are developed.

That is the mission of PMK Group: to stand at the crossroads of science and capital, to align vision with execution, and to transform risk into resilience.

This is who we are. And this is why we exist.

Timecode:

00:00 Introduction to Success in Biotech

00:16 Understanding the Main Risks in Biotech

00:44 Meet the Leader: Peter M. Kovacs

01:06 The PMK Group Difference

01:42 Minimizing Technical Failures

02:09 Supporting Biotech and MedTech Companies

02:32 Vision for the Future

02:58 Call to Collaborate

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Transcript:

Success in biotech requires more than just capital. It requires partnership built on expertise and shared risk. That's why at PMK Group, we invest not just money, but primary, our experiences. What are the main risks? The main risk is the failure, how we can avoid the failures. We are talking about the technical failures.

Studies show that around 60%, yes, 60% of clinical trial failures are due to technical reasons. We try to save billions of dollars and help the society to bring these drugs and products to the market as soon as possible. I'm Peter m Coax. I'm the leader and the CEO of BMP Group, which was this. Established to support the biotech and MedTech ecosystem.

I started as a clinical pharmacologist. From the research I moved to the clinical research and now in investment. I saw and experienced a lot of gaps, uh, within this drug development, um, life cycle. So at PMK Group, we realized a very high inefficiency during this drug development and medical technology development.

The main difference between PMK group and traditional investors that we are not just putting in our money, but we are putting in all our expertise and knowledge. And based on this full involvement into the drug development process, we can minimize the risk and also just shortening the development parts.

We are talking about the technical failures. Technical failures are very high. We can help making, uh, this failure rate close to zero. We are deeply involved in the planning, the structure, and planning the regulatory framework to developing the. Protocol and the scientific pathway of the entire drug development process.

After that, we are continuously hand in hand. We are working together with our target companies. Many of these small biotech and med tech companies are suffering to go to the clinic. From the laboratory, so we are the strongest to help them to move from preclinical to the clinic. At PMK Group, we are putting our expertise and professional services for equity in addition to our cash investments.

To our portfolio companies. My vision for the next five, 10 years that PMP group, we are able to help the patients to get lifesaving treatments and diagnostics, or even prevent the disease much faster and much easier way than the current business environment is helping for them. Building this effective ecosystem requires the right partners, truly innovative startups, and aligned forward thinking industry.

If you think you would be a good partner for us, please contact us and we'll be very happy to collaborate with you.